

CORPORATE PROFILE

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies and the company generates more than \$5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

STOCK PERFORMANCE

BIIB (COMMON STOCK)

Exchange NASDAQ (US Dollar)
 Price **\$313.97**
 Change (%) ▼ 0.01 (0.00%)
 Volume 907,441
 52 Week Low \$244.28
 Market Cap \$66,397,413,596
 Rolling EPS 16.31
 PE Ratio 19.25
 Shares Outstanding 211,476,936
 Data as of 11/17/17 4:00 p.m. ET



RECENT PRESS RELEASES

- 11/02/17
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab
- 11/02/17
Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
- 11/01/17
The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
- 10/27/17
Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
- 10/25/17
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis

UPCOMING EVENTS

There are currently no events scheduled.

RECENT SEC FILINGS

| FILING DATE | FORM |
|-------------|------|
| 11/16/17 | 3 |
| 11/07/17 | 8-K |
| 10/24/17 | 10-Q |
| 10/24/17 | 8-K |
| 08/31/17 | 4 |

ANALYST ESTIMATES / RATINGS

Mean Recommendation: 2.1



Sell

Strong Buy

EPS TREND

| | | Current | 30 Days Ago | 90 Days Ago |
|-----|--------|---------|-------------|-------------|
| QTR | Dec 17 | 5.59 | 5.59 | 5.55 |
| QTR | Mar 18 | 5.76 | 5.53 | 5.42 |
| QTR | Jun 18 | 6.06 | 5.81 | 5.73 |
| QTR | Sep 18 | 6.12 | 5.92 | 5.86 |
| F Y | Dec 17 | 22.08 | 21.54 | 21.44 |
| F Y | Dec 18 | 23.79 | 23.19 | 23.09 |

OWNERSHIP SUMMARY

| | Holders | Value (\$MM) | % O/S | Shares |
|-------------|---------|--------------|-------|-------------|
| Institution | 1,477 | 60,663.42 | 92.0 | 194,443,704 |
| Mutual Fund | 2,617 | 34,439.65 | 54.3 | 114,871,739 |
| Insider * | 21 | 63.56 | 0.1 | 246,643 |

**Insider values reflect direct beneficial ownership.*

| | Shares Held | % O/S | Share Change | Filing Date |
|---|-------------|-------|--------------|-------------|
| PRIMECAP Management Company | 15,212,914 | 7.2 | -178,487 | 09/30/17 |
| The Vanguard Group, Inc. | 14,668,942 | 6.9 | 134,115 | 09/30/17 |
| BlackRock Institutional Trust Company, N.A. | 11,866,817 | 5.6 | -320,324 | 09/30/17 |
| T. Rowe Price Associates, Inc. | 10,681,378 | 5.1 | 1,732,596 | 09/30/17 |
| State Street Global Advisors (US) | 9,669,416 | 4.6 | -51,896 | 09/30/17 |
| ClearBridge Investments, LLC | 9,250,827 | 4.4 | -43,073 | 09/30/17 |
| Fidelity Management & Research Company | 7,008,889 | 3.3 | 1,029,679 | 09/30/17 |
| Wellington Management Company, LLP | 5,167,662 | 2.4 | -60,818 | 09/30/17 |
| AllianceBernstein L.P. | 2,687,665 | 1.3 | 283,918 | 09/30/17 |
| Nuveen LLC | 2,456,104 | 1.2 | 207,109 | 09/30/17 |

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed